<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/css/bootstrap.min.css">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link
        href="https://fonts.googleapis.com/css2?family=Inter:ital,opsz,wght@0,14..32,100..900;1,14..32,100..900&family=Pacifico&display=swap"
        rel="stylesheet">
    <link rel="stylesheet" href="css/all.min.css">
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/main.css">
    <link rel="stylesheet" href="css/prescribing.css">
    <title>Mounjaro</title>

</head>

<body>

    <!-- diabetes page -->
    <nav class="navbar navbar-expand-lg navbar-light p-lg-0 bg-white position-fixed fixed-top ">

        <div class="container">
            <a class="navbar-brand" href="home.html">
                <img src="images/logoMounjaro.svg" alt="MounjaroLogo" class="w-100">

            </a>
            <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarNav">
                <span class="navbar-toggler-icon"></span>
            </button>

            <div class="collapse navbar-collapse" id="navbarNav">
                <ul class="navbar-nav mx-auto">
                    <li class="nav-item">
                        <a class="nav-link mx-2 " href="home.html">Home</a>
                    </li>
                    <li class="nav-item dropdown">
                        <a class="nav-link mx-2 dropdown-toggle" href="obesity.html" role="button"
                            data-bs-toggle="dropdown">Obesity</a>
                        <ul class="dropdown-menu">
                            <li><a class="dropdown-item" href="obesity.html" id="obesityWorks">How MOUNJARO works</a>
                            </li>
                            <li><a class="dropdown-item" href="efficacyObesity.html" id="efficacyObesity">Efficacy &
                                    Safety</a></li>
                            <li><a class="dropdown-item" href="obesity.html" id="obesityWorks">Instructions on how to
                                    use</a></li>
                        </ul>
                    </li>
                    <li class="nav-item dropdown">
                        <a class="nav-link mx-2 dropdown-toggle " href="diabetes.html" role="button"
                            data-bs-toggle="dropdown">Diabetes</a>
                        <ul class="dropdown-menu">
                            <li><a class="dropdown-item" href="diabetes.html" id="diabetesWorks">How MOUNJARO works</a>
                            </li>
                            <li><a class="dropdown-item" href="efficacyDiabetes.html" id="efficacyDiabetes">Efficacy &
                                    Safety</a></li>
                            <li><a class="dropdown-item" href="diabetes.html" id="diabetesWorks">Instructions on how to
                                    use</a></li>
                        </ul>
                    </li>
                    <li class="nav-item">
                        <a class="nav-link mx-2 active" href="#" id="prescribing">Prescribing Info</a>
                    </li>
                    <li class="nav-item dropdown">
                        <a class="nav-link mx-2 dropdown-toggle" href="#" role="button"
                            data-bs-toggle="dropdown">Education Hub</a>
                        <ul class="dropdown-menu">
                            <li><a class="dropdown-item" href="#" id="podcasts">podcasts</a></li>
                            <li><a class="dropdown-item" href="#" id="videos">videos</a></li>
                        </ul>
                    </li>
                </ul>
            </div>
        </div>
    </nav>


    <header class="container">
        <div class="pt-15">
            <h3>Abbreviated Prescribing Information</h3>
            <h4 class="color py-3">NAME OF THE MEDICINAL PRODUCT</h4>
        </div>
        <p class="p-0 m-1">Mounjaro™ 2.5 mg solution for injection in vial</p>
        <p class="p-0 m-1">Mounjarot™ 5 mg solution for injection in vial</p>
        <p class="p-0 m-1">Mounjarot™ 7.5 mg solution for injection in vial</p>
        <p class="p-0 m-1">Mounjarot™ 10 mg solution for injection in vial</p>
        <p class="p-0 m-1">Mounjarot™ 12.5 mg solution for injection in vial</p>
        <p class="p-0 m-1">Mounjarot™ I5 mg solution for injection in vial</p>
        <h4 class="color py-3">QUALITATIVE AND QUANTITATIVE COMPOSITION</h4>
        <p>Mounjaro™ 2.5 mg solution for injection in vial <br>
            Each vial contains 2.5 mg of tirzepatide in 0.5 ml solutions.</p>

        <p>Mounjarot™ 5 mg solution for injection in vial <br>
            Each vial contains 5 mg of tirzepatide in 0.5 ml solutions.</p>

        <p>Mounjarot™ 7.5 mg solution for injection in vial <br>
            Each vial contains 7.5 mg of tirzepatide in 0.5 ml solutions.</p>

        <p>Mounjarot™ 10 mg solution for injection in vial <br>
            Each vial contains 10 mg of tirzepatide in 0.5 ml solutions.</p>

        <p>Mounjarot™ 12.5 mg solution for injection in vial <br>
            Each vial contains 12.5 mg of tirzepatide in 0.5 ml solutions.</p>

        <p>Mounjarot™ I5 mg solution for injection in vial <br>
            Each vial contains 15 mg of tirzepatide in 0.5 ml solutions.</p>
        <h4 class="color py-3">PHARMACEUTICAL FORM</h4>
        <p>Solution for subcutaneous injection.</p>
        <p>Clear to opalescent. colorless to slightly yellow or brown, essentially free of particles. sterile.
            preservative free.</p>

        <h4 class="my-5">
            CLINICAL PARTICULARS <br>
            <span id="Therapeutic">Therapeutic indications</span>
        </h4>
        <h5 class="color text-decoration-underline my-2">Type 2 diabetes mellitus</h5>
        <p>Mounjaro™ is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as
            an adjunct to diet and exercise..</p>
        <ul>
            <li>
                As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
            </li>
            <li>
                In addition to other medicinal products for the treatment of diabetes
            </li>
        </ul>
        <h5 class="color text-decoration-underline my-2">Weight management</h5>
        <p>Mounjar™ is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight
            management. including weight loss and weight maintenance. in adults with an
            initial Body Mass Index (BMI) Of</p>
        <ul>
            <li>
                ≥ 30 kg/m2 (obesity) or
            </li>
            <li>
                ≥ 27 kg/m2 to &lt; 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid
                condition

            </li>
        </ul>
        <p>(e.g. hypertension, dyslipidaemia. obstructive sleep apnoea. cardiovascular <br>
            disease, prediabetes. or type 2 diabetes mellitus).</p>

        <h4 class="my-5" id="Posology">
            Posology and method of administration
        </h4>
        <h5 class="color text-decoration-underline my-2">Posology</h5>
        <p class="py-1">The starting dose of tirzepatide is 2.5 mg once weekly. After 4 weeks, the dose should be
            increased to 5 mg
            once
            weekly. If needed. dose increases can be made in 2.5 mg increments
            after a minimum of 4 weeks on the current dose.</p>
        <p class="py-1">The recommended maintenance doses are 5 mg. 10 mg and 15 mg.</p>
        <p class="py-1">The maximum dose is 15 mg once weekly.</p>
        <p class="py-1">When tirzepatide is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor
            (SGLT2i)
            therapy, the current dose of metformin and/or SGLT2i can be continued.</p>
        <p class="py-1"> When tirzepatide is added to existing therapy of a sulphonylurea and/or insulin, a reduction in
            the dose of
            sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemk
            Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and insulin. A stepwise
            approach
            to insulin reduction is recommended.</p>

        <div>
            <h5 class="color text-decoration-underline my-2">Missed doses</h5>
            <p>If a dose is missed, it should be administered as soon as possible within 4 days after the missed dose.
                If
                more than 4 days have passed, skip the missed dose and administer the next
                dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly
                dosing
                schedule.</p>
            <h5 class="color text-decoration-underline my-2">Changing the dosing schedule</h5>
            <p>The day of weekly administration can be changed, if necessary,
                as long as the time between two doses is at least 3 days.</p>
            <h5 class="color text-decoration-underline my-2">Method of administration</h5>
            <p>Mounjaro™ is to be injected subcutaneously in the abdomen, thigh or upper arm.</p>

        </div>
        <div class="my-5">
            <p>
                The dose can be administered at any time of day, with or without meals.

            </p>
            <p>
                Injection sites should be rotated with each dose. If a patient also injects insulin, they should inject
                Mounjaro™ into a different injection site.

            </p>
            <p>
                Patients should be advised to carefully read the instructions for use included with the package leaflet
                before administering the medicinal product.

            </p>
            <p>
                Patients and their caregivers should be trained in subcutaneous injection technique before administering
                Mounjaro™.

            </p>
        </div>


        <h4 id="Contraindications">Contraindications</h4>
        <p>Hypersensitivity to the active substance.</p>
        <h4 id="Special">Special warnings and precautions for use</h4>


        <div>
            <h5 class="color text-decoration-underline my-2">Actual pancreatitis</h5>
            <p>Tirzepatide has not been studied in patients with a history of pancreatitis, and should be used with
                caution
                in these patients.</p>
            <p>Acute pancreatitis has been reported in patients treated with tirzepatide.</p>
            <p>Patients should be informed Of the symptoms Of acute pancreatitis. If pancreatitis is suspected,
                tirzepatide
                should be discontinued. If the diagnosis Of pancreatitis is confirmed,
                tirzepatide should not be restarted. In the absence Of other signs and symptoms Of acute pancreatitis,
                elevations in pancreatic enzymes alone are not predictive Of acute pancreatitis.</p>

            <h5 class="color text-decoration-underline my-2">Hypoglycaemia</h5>
            <p>Patients receiving tirzepatide in combination with an insulin secretagogue (for example. a sulphonylurea)
                or insulin have an increased risk of hypoglycaemia. The risk of
                hypoglycaemia may be lowered by a reduction in the dose of the insulin secretagogue or insulin.</p>


            <h5 class="color text-decoration-underline my-2 mt-4">Gastrointestinal effects</h5>
            <p>Tirzepatide has been associated with gastrointestinal adverse reactions, which include nausea, vomiting.
                and diarrhoea. These adverse reactions may lead to dehydration which could
                lead to a deterioration in renal function including acute renal failure. Patients treated with
                tirzepatide should be advised of the potential risk of dehydration, due to the gastrointestina
                adverse reactions and take precautions to avoid fluid depletion and electrolyte disturbances. This
                should particularly be considered in the elderly, who be more susceptible to such
                complications.</p>


            <h5 class="color text-decoration-underline my-2 mt-4">Severe gastrointestinal disease</h5>
            <p>Tirzepatide has not been studied in patients with severe gastrointestinal disease, including severe
                gastroparesis, and should be used with caution in these patients.</p>


            <h5 class="color text-decoration-underline my-2 mt-4">Diabetic retinopathy</h5>
            <p>Tirzepatide has not been studied in patients with non-proliferative diabetic retinopathy requiring acute
                therapy, proliferative diabetic retinopathy or diabetic macular oedema, and
                should be used with caution in these patients with appropriate monitoring.</p>

            <h5 class="color text-decoration-underline my-2 mt-4">Sodium content</h5>
            <p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially
                'sodium-free'.</p>

            <h4 class="mt-3" id="Fertility">Fertility, pregnancy and lactation</h4>

            <h5 class="color text-decoration-underline my-2 mt-4">pregnancy</h5>
            <p>There are no or a limited amount of data from the use of tirzepatide in pregnant women. Studies in
                animals have shown reproductive toxicity. Tirzepatide is not recommended during
                pregnancy and in women of childbearing potential not using contraception.</p>


            <h5 class="color text-decoration-underline my-2 mt-4">breast-feeding</h5>
            <p>It is unknown whether tirzepatide is excreted in human milk. A risk to the newborn/infant cannot be
                excluded.</p>
            <p>
                A decision must be mode whether to discontinue breast-feeding or to discontinue/abstain from tirzepatide
                therapy taking into account the benefit of breast-feeding for the child and
                the benefit of therapy for the woman.</p>


            <h5 class="color text-decoration-underline my-2 mt-4">Fertility</h5>
            <p>The effect of tirzepatide on fertility in humans is unknown. <br>
                Animal studies with tirzepatide did not indicate direct harmful effects with respect to fertility.</p>

            <h4>Effects on ability to drive and use machines</h4>
            <p>Tirzepatide has no or negligible influence on the ability to drive or use machines. When tirzepatide is
                used in combination with a sulphonylurea or insulin patients should be advised to
                take precautions to avoid hypoglycaemia while driving and using machines.</p>

            <h5 class="mt-5" id="Undesirable">Undesirable effects</h5>
            <h5 class="color text-decoration-underline my-2 mt-4">Tabulated list of adverse reactions</h5>
            <p>The following related adverse reactions from clinical studies are listed below by system organ class and
                in order of decreasing incidence (very common: ≥1/10; common: ≥1/100 to &lt;1 / 10). <br>
                Within each
                incidence
                grouping, adverse reactions are presented in order of decreasing frequency.</p>

            <h5 class="mt-5">Adverse reactions</h5>
            <img src="images/info.png" alt="info" class="w-100">
            <p>'Clinically significant hypoglycaemia (blood glucose &lt;3.0 mmol/L (&lt;54 mg/dL) or severe hypogycaemia
                (requiring the assistance of another person)) occurred in 10 to 14% (0.14 to 0.16 events/patient
                year) of patients when tirzepatide was added to sulphonylurea and in 14 to 19% (0.43 to 0.64
                events/patient year) Of patients when tirzepatide was added to basal insulin. <br>
                'Fatigue includes the
                terms fatigue. asthenia. malaise. and lethargy. <br>
                <sup>1</sup>Adverse reaction that only applies to patients with 2 diabetes mellitus (T2DM). <br>
                <sup>2</sup>Adverse reaction that mainly applies to patients with overweight or obesity, with or without
                T2DM.
            </p>

            <div class="mb-5 pb-5">
                <p class="m-0">✔ Always read the full prescribing information.</p>
                <p class="m-0">✔ Healthcare professionals are asked to report any suspected adverse drug reactions to
                    the Egyptian
                    pharmacovigilance center (EPVC).</p>
                <p class="m-0">✔ Egyptian drug authority Mounjaro™ 2.5, 5 mg solution for injection approval date:
                    13/3/2024.</p>
            </div>


        </div>
    </header>

    <button class="btn scroll-top-btn">
        <img src="images/Top.png" alt="top">
    </button>
    <!-- footer -->
    <footer class="footer">
        <div class="container">
            <div class="row g-sm-4 justify-content-around">
                <!-- Column 1 -->
                <div class="col-md-2">
                    <h6><strong>Home</strong></h6>
                    <a class="text-secondary" href="#" id="indication">Indication</a>
                </div>

                <!-- Column 2 -->
                <div class="col-md-2">
                    <h6><strong>Obesity</strong></h6>
                    <a class="footer-color" href="#" id="obesityWorks">How MOUNJARO works</a><br>
                    <a class="footer-color" href="#" id="efficacyObesity">Efficacy & Safety</a><br>
                    <a class="footer-color" href="#" id="obesityWorks">Instructions on how to use</a><br>
                    - <a class="footer-color" href="#" id="vials">Vials</a><br>
                    - <a class="footer-color" href="#" id="kwipens">Kwikpens</a>
                </div>

                <!-- Column 3 -->
                <div class="col-md-2">
                    <h6><strong>Diabetes</strong></h6>
                    <a class="footer-color" href="#" id="diabetesWorks">How MOUNJARO works</a><br>
                    <a class="footer-color" href="#" id="efficacyDiabetes">Efficacy & Safety</a><br>
                    <a class="footer-color" href="#" id="diabetesWorks">Instructions on how to use</a><br>
                    - <a class="footer-color" href="#" id="vials">Vials</a><br>
                    - <a class="footer-color" href="#" id="kwipens">Kwikpens</a>

                </div>

                <!-- Column 4 -->
                <div class="col-md-3">
                    <h6><strong>Prescribing info</strong></h6>
                    <a class="footer-color" href="#Therapeutic">Therapeutic indications</a><br>
                    <a class="footer-color" href="#Posology">Posology and method of administration</a><br>
                    <a class="footer-color" href="#Contraindications">Contraindications</a><br>
                    <a class="footer-color" href="#Special">Special warnings and precautions for use</a><br>
                    <a class="footer-color" href="#Fertility">Fertility, pregnancy and lactation</a><br>
                    <a class="footer-color" href="#Undesirable">Undesirable effects</a>
                </div>

                <!-- Column 5 -->
                <div class="col-md-2">
                    <h6><strong>Education Hub</strong></h6>
                    <a class="footer-color" href="#" id="podcasts">Podcasts</a><br>
                    <a class="footer-color" href="#" id="videos">Videos</a>
                </div>

                <!-- Logo Column -->

                <div class=" d-flex gap-4 align-items-center justify-content-between">
                    <div>
                        <img src="images/logoMounjaro.svg" alt="MounjaroLogo" class="w-100">

                    </div>
                    <div>
                        <p class="footer-color">© 2024 Mounjaro® (tirzepatide). All rights reserved.</p>
                    </div>
                </div>
            </div>
        </div>
    </footer>


    <script src="js/bootstrap.bundle.js"></script>
    <script src="js/main.js"></script>
    <script src="js/prescribing.js"></script>
</body>

</html>